Related content

Influence of Cytochrome P450 (CYP) 3A5 Polymorphisms on the Pharmacokinetics of Lansoprazole Enantiomers in CYP2C19 Extensive Metaboliser Renal Transplant Recipients

By Miura Masatomo  

Clinical Drug Investigation, Vol. 27, Iss. 4, 2007-01 ,pp. : 251-258

Adis International

Access to resources Recommend Favorite

The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects

By Xu Hong-Rong   Chen Wei-Li   Li Xue-Ning   Chu Nan-Nan  

Pharmaceutical Biology (Formerly International Journal of Pharmacognosy), Vol. 48, Iss. 8, 2010-08 ,pp. : 947-952

Informa Healthcare

Access to resources Recommend Favorite

A pharmacokinetic/pharmacodynamic analysis of a standard voriconazole regimen in different CYP2C19 genotypes by Monte Carlo simulation

By  

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 70, Iss. 5, 2015-01 ,pp. : 306-309

Govi-Verlag

Access to resources Recommend Favorite

Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations

By Uno Tsukasa   Niioka Takenori   Hayakari Makoto   Yasui-Furukori Norio   Sugawara Kazunobu   Tateishi Tomonori  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 2, 2007-02 ,pp. : 143-149

Springer Publishing Company

Access to resources Recommend Favorite

Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes

By Shimizu Mikiko   Uno Tsukasa   Yasui-Furukori Norio   Sugawara Kazunobu   Tateishi Tomonori  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 8, 2006-08 ,pp. : 597-603

Springer Publishing Company

Access to resources Recommend Favorite